相关实验视频

Updated: Jun 18, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

一个尺寸真的适合所有吗? 在干预性心脏病学中,个性化抗血小板治疗的理由

Ahmed Elserwey^1,2, Richard J Jabbour², Nick Curzen^1,2

¹Faculty of Medicine, University of Southampton.

Future cardiology

|August 2, 2024

概括

双抗血小板疗法 (DAPT) 是急性冠状动脉综合征和支架后的标准,但个性化P2Y12抑制剂单疗可能提供更好的结果,降低出血风险.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
干预心脏病学干预心脏病学

背景情况:

心血管疾病仍然是全球主要的死亡原因.
双重抗血小板治疗 (DAPT),结合阿司匹林和P2Y12抑制剂,是急性冠状动脉综合征 (ACS) 和皮肤冠状动脉干预 (PCI) 后的标准治疗方法.
目前的DAPT协议面临的挑战是阿司匹林的必要性,药物释放后支架 (DES) 植入的最佳持续时间,P2Y12抑制剂的选择以及个体患者的反应变化.

研究的目的:

评估当前DAPT策略的有效性和安全性.
为了探索P2Y12抑制剂单一治疗的潜在益处.
质疑"适合所有人"的方法,并倡导个性化抗血小板治疗策略.

主要方法:

关于DAPT和P2Y12抑制剂单一治疗的最新临床数据和指导方针的审查.
分析与不同抗血小板治疗方案相关的抗缺血作用和出血风险.
对当前DAPT持续时间建议和P2Y12抑制剂选择的比较评估.

主要成果:

新出现的证据表明,单独使用P2Y12抑制剂可以提供足够的抗胰岛症益处,同时显著降低出血风险.
在DAPT持续时间指南和P2Y12抑制剂选择中的不一致性在临床实践中造成了不确定性.
个体患者对抗血小板剂的反应各不相同,突出显示了统一治疗方案的局限性.

结论:

当前的默认DAPT策略可能不适合所有患者.
对抗血小板治疗的个性化方法,可能涉及P2Y12抑制剂单一治疗,需要进一步调查.
根据个体患者的因素和反应量身定制治疗对于优化心血管疾病管理结果至关重要.

关键词:

在CYP2C19 LOF中.在TEG 6S中,我们可以使用TEG 6S.急性冠状动脉综合征急性冠状动脉综合征抗血小板药物是一种抗血小板药.基因型基因型基因型缺血性心脏病是一种心脏病.个性化抗血小板治疗是个性化的抗血小板治疗.现象型现象型是一种现象型.血小板功能测试试验血小板功能测试

更多相关视频

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...